Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
Open Access
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON StudyJournal of Clinical Oncology, 2021
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal CancerNew England Journal of Medicine, 2020
- Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONOBritish Journal of Cancer, 2020
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerNew England Journal of Medicine, 2019
- A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ studyEuropean Journal of Cancer, 2019
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and IrinotecanJAMA Oncology, 2019
- BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionBritish Journal of Cancer, 2015
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013